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Conclusions: This initial feasibility and safety study of renal nerve denervation mediated
by low and intermediate -radiation dosages indicates that this approach can cause
substatntial nerve damage while avoiding significant damage to the renal artery.
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Background: Renal sympathetic denervation is a novel treatment option in patients with
treatment resistant hypertension. Registry data allow to evaluate safety and efficacy in a
real-world szenario.
Methods: 53 consecutive patients with treatment resistant hypertension underwent renal
sympathetic denervation with the Symplicity radiofrequency based catheter. At baseline,
mean office blood pressure was 17122/9317 mm Hg. The mean number of
antihypertensive agents was 5.0.
Results: At 6 months follow up, office systolic blood pressure improved to 15118 mm
Hg (minus 20 mm Hg compared to baseline; p0.0001), the diastolic blood pressure to
8611 mm Hg (minus 7 mm Hg compared to baseline, p0.001). The response rate,
defined as reduction of office systolic blood pressure of 10 mm Hg was 66%. In 9
Patients (17%), number of dosage of antihypertensive agents could be reduced. The mean
number of ablations points per kidney was 4.3. There was no correlation between the
number of ablation points and blood pressure response (r 0,25, pns).
Conclusions: Renal sympathetic denervation with the Simplicity systems results in a
significant reduction of office systolic and diastolic blood pressure reduction in patients
with treatment resistant hypertension. Effects on blood pressure were somewhat less
profound than reported in the Symplicity trial program, reflecting a real world szenario
with more liberal use of the method. Interestingly, there was no correlation between the
number of ablation points and blood pressure response.
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Background: Resistant hypertension is associated with significant cardiovascular mor-
bidity and mortality and it poses a significant treatment challenge for physicians. The
treatment of resistant hypertension by renal sympathetic denervation (RD) has demon-
strated excellent short-term reductions in blood pressure (BP) at six-months as reported by
the Symplicity HTN-2 Investigators. The future role of RD is evolving and long-term
results will clarify it’s durability. Here we assess the long-term results in the first cohort
of patients to be treated with RD in Australia.
Methods: We compared the baseline office-based BP to long-term follow-up office-based
BP, number of prescribed anti-hypertensive medications, major adverse cardiac and
cerebrovascular events (MACCE) and hospital admissions in 8 patients whom had
undergone RD from July 2007 to January 2008.
Results: Our cohort had a mean follow-up of 43 months and we found that office-based
BP measurements were reduced by a mean of 30/9 mmHg when compared to baseline
measurements (p0.003 systolic; p0.09 diastolic). The mean number of prescribed
anti-hypertensive medications remained stable throughout the follow-up period (4.88
medications pre-treatment vs 4.1 medications at follow-up; pNS). Two patients required
hospitalisation for late cerebrovascular events. There were no cardiac events reported.
Conclusions: This is the longest reported follow-up of renal sympathetic denervation
patients. We have demonstrated a significant and durable decrease in blood pressure.
However, there has been no reduction in the number of prescribed anti-hypertensive
medications.
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Background: Renal denervation (RDN) is a promising new treatment option for
pronounced hypertension refractory to medical therapy. Interestingly, only 70-80% of
patients have a relevant reduction in blood pressure (BP) three to six months after RDN
when assessed by systematic 24h BP measurements. No variables have been identified to
date predicting the BP response.
Methods: We assessed 11 patients with bilateral renal denervation for the changes of pre-
and postprocedural norepinephrine (NE) and epinephrine (E) levels measured directly
from the renal artery (RA) and vein (RV). We defined the respective spillover for NE
and E as the difference RV-RA and compared this difference before and after the
procedure.
Results: We assessed NE and E for 88 probes (11 patients x 2 (bilateral probes) x 2 (RA
and RV) x 2(pre- and post-procedural)). There was a significant decrease of the NE
RV-RA spill-over comparing pre- with post-procedural levels (184pg/ml180 decrease
to 97pg/ml137, P0.03 for paired t-test). There was no significant change in the
epinephrine levels during the procedure under conscious sedation (56pg/ml192 com-
pared to 29pg/ml171, P0.62 for paired t-test). The pre-post NE RV-RA was even
more pronounced when the median values were compared (P  0.02).
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